Iridex (IRIX) said late Wednesday a peer-reviewed study showed the "sustained safety and efficacy" of MicroPulse Transscleral Laser Therapy in managing both primary and secondary glaucoma over five years.

"These findings suggest MicroPulse TLT can be a viable alternative to invasive incisional glaucoma surgery, particularly in patients with secondary glaucoma and those for whom incisional surgery may be challenging," said Ronald de Crom, who conducted the study with colleagues at the University Eye Clinic Maastricht, Netherlands.

The study assessed 165 pre- and post-cataract eyes treated between 2016 and 2019, with 112 eyes completing the five-year follow-up, the company said. The study was published in Ophthalmology Therapy.

The company's shares surged 20% in recent after-hours trading.